EGFR c.523_525delinsCAA ;(p.N175Q)

Variant ID: 7-55214397-AAC-CAA

NM_005228.3(EGFR):c.523_525delinsCAA;(p.N175Q)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.

Frontiers In Immunology
Li, Wei W; Zhu, Zhongyu Z; Chen, Weizao W; Feng, Yang Y; Dimitrov, Dimiter S DS
Publication Date: 2017

Variant appearance in text: EGFR: N175Q
PubMed Link: 29181010
Variant Present in the following documents:
  • Main text
  • fimmu-08-01554.pdf
View BVdb publication page



Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.

Protein & Cell
Mimura, Yusuke Y; Katoh, Toshihiko T; Saldova, Radka R; O'Flaherty, Roisin R; Izumi, Tomonori T; Mimura-Kimura, Yuka Y; Utsunomiya, Toshiaki T; Mizukami, Yoichi Y; Yamamoto, Kenji K; Matsumoto, Tsuneo T; Rudd, Pauline M PM
Publication Date: 2018-01

Variant appearance in text: EGFR: N175Q
PubMed Link: 28597152
Variant Present in the following documents:
  • Main text
  • 13238_2017_Article_433.pdf
View BVdb publication page